6.0 KiB
| title | chunk | source | category | tags | date_saved | instance |
|---|---|---|---|---|---|---|
| Chronic condition | 5/6 | https://en.wikipedia.org/wiki/Chronic_condition | reference | science, encyclopedia | 2026-05-05T07:27:07.415511+00:00 | kb-cron |
=== Canada === The Public Health Agency of Canada states that chronic disease has a negative impact on the labor force participant of individuals. In particular, people with chronic diseases "are likely to have recurrent sick leave, long-term absences from work, and often face an early retirement from the labour force." In 2000, the Public Health Agency of Canada stated that the total economic burden of arthritis totaled 6.4 billion Canadian dollars per year, representing 28.9% of all musculoskeletal disease expenditures. 65% of the total economic cost was incurred by those aged 35-64 years old. It is anticipated that people aged 55 and older will most significantly contribute to the prevalence of arthritis. This is projected to result in reduced labor force participant and a substantial increase in morbidity costs. The Public Health Agency of Canada recommends focusing on prevention strategies, minimizing costs by improving health and reducing disability, and providing support to people with arthritis to remain active in the workforce.
=== Japan === As of 2004, the estimated economic burden of Chronic obstructive pulmonary disease (COPD) is 805.5 billion yen per year. Direct costs, which include inpatient care, outpatient care, and home oxygen therapy, account for 645.1 billion yen per year. Meanwhile, indirect costs are estimated to cost 160.4 billion yen per year in lost productivity due to absenteeism from work. The high smoking rate and increasing size of the elderly population are likely to exacerbate the economic impact of COPD in Japan. Major indirect costs of COPD are a decrease in labor force participation, increased cost of healthcare due to assisted living expenses, increased prevalence of premature death, and care giver support cost. In 1999, a survey demonstrated that patients with chronic bronchitis, COPD, or emphysema missed an average of 42.2 days of work per year due to their condition.
== Social and personal impact == There have been recent links between social factors and prevalence as well as outcome of chronic conditions.
=== Mental health === The connection between loneliness, overall health, and chronic conditions has recently been highlighted. Some studies have shown that loneliness has detrimental health effects similar to that of smoking and obesity. One study found that feelings of isolation are associated with higher self reporting of health as poor, and feelings of loneliness increased the likelihood of mental health disorders in individuals. The connection between chronic illness and loneliness is established, yet oftentimes ignored in treatment. One study for example found that a greater number of chronic illnesses per individual were associated with feelings of loneliness. Some of the possible reasons for this listed are an inability to maintain independence as well as the chronic illness being a source of stress for the individual. A study of loneliness in adults over age 65 found that low levels of loneliness as well as high levels of familial support were associated with better outcomes of multiple chronic conditions such as hypertension and diabetes. There are some recent movements in the medical sphere to address these connections when treating patients with chronic illness. The biopsychosocial approach for example, developed in 2006 focuses on patients "patient's personality, family, culture, and health dynamics." Physicians are leaning more towards a psychosocial approach to chronic illness to aid the increasing number of individuals diagnosed with these conditions. Despite this movement, there is still criticism that chronic conditions are not being treated appropriately, and there is not enough emphasis on the behavioral aspects of chronic conditions or psychological types of support for patients. The mental health intersectionality on those with chronic conditions is a large aspect often overlooked by doctors. And chronic illness therapists are available for support to help with the mental toll of chronic illness as it is often underestimated in society. Adults with chronic illness that restrict their daily life present with more depression and lower self-esteem than healthy adults and adults with non-restricting chronic illness. The emotional influence of chronic illness also has an effect on the intellectual and educational development of the individual. For example, people living with type 1 diabetes endure a lifetime of monotonous and rigorous health care management usually involving daily blood glucose monitoring, insulin injections, and constant self-care. This type of constant attention that is required by type 1 diabetes and other chronic illness can result in psychological maladjustment. There have been several theories, namely one called diabetes resilience theory, that posit that protective processes buffer the impact of risk factors on the individual's development and functioning.
=== Financial cost === People with chronic conditions pay more out-of-pocket; a study found that Americans spent $2,243 more on average. The financial burden can increase medication non-adherence. In some countries, laws protect patients with chronic conditions from excessive financial responsibility; for example, as of 2008 France limited copayments for those with chronic conditions, and Germany limits cost sharing to 1% of income versus 2% for the general public. Within the medical-industrial complex, chronic illnesses can impact the relationship between pharmaceutical companies and people with chronic conditions. Life-saving drugs, or life-extending drugs, can be inflated for a profit. There is little regulation on the cost of chronic illness drugs, which suggests that abusing the lack of a drug cap can create a large market for drug revenue. Likewise, certain chronic conditions can last throughout one's lifetime and create pathways for pharmaceutical companies to take advantage of this.